Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease

Human Molecular Genetics

Volumn 25, Issue 9, 2016, Pages 1739-1753

  Yin, Xiangling ^a   Manczak, Maria ^a   Reddy, P Hemachandra ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ELAMIPRETIDE; GUANOSINE TRIPHOSPHATASE; HUNTINGTIN; HYDROGEN PEROXIDE; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOQ; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; 10-(6'-UBIQUINONYL)DECYLTRIPHENYLPHOSPHONIUM BROMIDE; ARGINYL-2,'6'-DIMETHYLTYROSYL-LYSYL-PHENYLALANINAMIDE; MITOCHONDRIAL PROTEIN; OLIGOPEPTIDE; ORGANOPHOSPHORUS COMPOUND; UBIQUINONE;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRP1 GENE; DRUG TARGETING; FIS1 GENE; FUSION GENE; GENE EXPRESSION REGULATION; HUNTINGTON CHOREA; IMMUNOBLOTTING; LIPID PEROXIDATION; MFN1 GENE; MFN2 GENE; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL TOXICITY; MITOCHONDRION; MOUSE; NEUROPROTECTION; NONHUMAN; NRF1 GENE; NRF2 GENE; OPA1 GENE; PGC1ALPHA GENE; PGC1BETA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSD95 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNAPSE; SYNAPTOPHYSIN GENE; TFAM GENE; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; DRUG EFFECTS; GENETICS; HUMAN; HUNTINGTON DISEASE; METABOLISM; MUTATION; NERVE CELL; PATHOLOGY;

ANIMALS; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTATION; NEURONS; OLIGOPEPTIDES; ORGANOPHOSPHORUS COMPOUNDS; SYNAPSES; UBIQUINONE;

EID: 84991329907     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw045     Document Type: Article

References (53)

1. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E. D. and Richardson, E.P. Jr. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
2. Montoya, A., Price, B.H., Menear, M. and Lepage, M. (2006) Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatry. Neurosci., 31, 21-29.
3. Byers, R.K., Gilles, F.H. and Fung, C. (1973) Huntington's disease in children. Neuropathologic study of four cases. Neurology, 23, 561-569.
4. Spargo, E., Everall, I.P. and Lantos, P.L. (1993) Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J. Neurol. Neurosurg. Psychiatry, 56, 487-491.
5. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
6. Reddy, P.H., Williams, M. and Tagle, D.A. (1999) Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci., 22, 248-255.
7. Reddy, P.H., Mao, P. and Manczak, M. (2009) Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev., 61, 33-48.
8. Li, S. and Li, X.J. (2006) Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener., 1, 19.
9. Bates, G.P. (2005) History of genetic disease: the molecular genetics of Huntington disease-a history. Nat. Rev. Genet., 6, 766-773.
10. Shirendeb, U., Reddy, A.P., Manczak, M., Calkins, M.J., Mao, P., Tagle, D.A. and Reddy, P.H. (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet., 20, 1438-1455.
11. Kim, J., Moody, J.P., Edgerly, C.K., Bordiuk, O.L., Cormier, K., Smith, K., Beal, M.F. and Ferrante, R.J. (2010) Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet., 19, 3919-3935.
12. Squitieri, F., Falleni, A., Cannella, M., Orobello, S., Fulceri, F., Lenzi, P. and Fornai, F. (2010) Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J. Neural. Transm. (Vienna), 117, 77-83.
13. Costa, V., Giacomello, M., Hudec, R., Lopreiato, R., Ermak, G., Lim, D., Malorni, W., Davies, K.J., Carafoli, E. and Scorrano, L. (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med., 2, 490-503.
14. Wang, H., Lim, P.J., Karbowski, M. and Monteiro, M.J. (2009) Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet., 18, 737-752.
15. Shirendeb, U., Calkins, M., Manczak, M., Dufour, B., McBride, J., Mao, P. and Reddy, P.H. (2012) Mutant huntingtin's association with mitochondria protein Drp1, and impaired axonal transport of mitochondria in Huntington's disease neurons. Hum. Mol. Genet., 21, 406-420.
16. Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M.A., Hayden, M.R. et al. (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med., 17, 377-382.
17. Manczak, M. and Reddy, P.H. (2015) Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease. Hum. Mol. Genet., 24, 7308-7325.
18. Reddy, P.H. and Shirendeb, U.P. (2012) Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta., 1822, 101-110.
19. Reddy, P.H. (2008) Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med., 10, 291-315.
20. Reddy, P.H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T.P., Anekonda, V., Shirendeb, U.P., Calkins, M.J., Reddy, A.P., Mao, P. and Manczak, M. (2012) Abnormal mitochondrial dynamics andsynaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim. Biophys. Acta, 1822, 639-649.
21. Szeto, H.H. (2008) Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann. N. Y. Acad. Sci., 1147, 112-1121.
22. Reddy, P.H. (2006) Mitochondrial oxidative damage in aging and Alzheimer's disease:implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006, 31372.
23. Sheu, S.S., Nauduri, D. and Anders, M.W. (2006) Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta., 1762, 256-265.
24. Murphy, M.P. and Smith, R.A. (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu. Rev. Pharmacol. Toxicol., 47, 629-656.
25. Smith, R.A. and Murphy, M.P. (2010) Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N Y Acad. Sci., 1201, 96-103.
26. Hwang, P.M., Bunz, F., Yu, J., Rago, C., Chan, T.A., Murphy, M. P., Kelso, G.F., Smith, R.A., Kinzler, K.W. and Vogelstein, B. (2001) Ferredoxin reductase affects p53-dependent, 5 fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med., 7, 1111-1117.
27. Jauslin, M.L., Meier, T., Smith, R.A. and Murphy, M.P. (2003) Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J., 17, 1972-1974.
28. Bedogni, B., Pani, G., Colavitti, R., Riccio, A., Borrello, S., Murphy, M., Smith, R., Eboli, M.L. and Galeotti, T. (2003) Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival. J. Biol. Chem., 278, 16510-16519.
29. Dhanasekaran, A., Kotamraju, S., Kalivendi, S.V., Matsunaga, T., Shang, T., Keszler, A., Joseph, J. and Kalyanaraman, B. (2004) Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem., 279, 37575-37587.
30. Manczak, M., Mao, P., Calkins, M.J., Cornea, A., Reddy, A.P., Murphy, M.P., Szeto, H.H., Park, B. and Reddy, P.H. (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis., 20 (Suppl. 2), S609-S631.
31. Szeto, H.H. (2006) Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPSJ. 8, E277-EW283.
32. Cho, J., Wo, K., Wu, D., Soong, Y., Liu, S., Szeto, H.H. and Hong, M.K. (2007) Potent mitochondria targeted peptides reduce myocardial infarction in rats. Coron. Artery. Dis., 18, 215-220.
33. Thomas, D.A., Stauffer, C., Zhao, K., Yang, H., Sharma, V.K., Szeto, H.H. and Suthanthiran, M. (2007) Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves post transplantation function. J. Am. Soc. Nephrol., 18, 213-222.
34. Cho, S., Szeto, H.H., Kim, E., Kim, H., Tolhurst, A.T. and Pinto, J.T. (2007) A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. J. Biol. Chem., 282, 4634-4642.
35. Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N.Y., Szeto, H.H. and Beal, M.F. (2006) Cellpermeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem., 98, 1141-1148.
36. Calkins, M.J., Manczak, M., Mao, P., Shirendeb, U. and Reddy, P.H. (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet., 20, 4515-4529.
37. Manczak, M., Calkins, M.J. and Reddy, P.H. (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet., 20, 2495-2509.
38. Wang, X., Su, B., Siedlak, S.L., Moreira, P.I., Fujioka, H., Wang, Y., Casadesus, G. and Zhu, X. (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. USA., 105, 19318-19323.
39. Wang, X., Su, B., Lee, H.G., Li, X., Perry, G., Smith, M.A. and Zhu, X. (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci., 29, 9090-9103.
40. Silva, D.F., Selfridge, J.E., Lu, J., Lezi, E.L., Roy, N., Hutfles, L., Burns, J.M., Michaelis, E.K., Yan, S., Cardoso, S.M. and Swerdlow, R.H. (2013) Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum. Mol. Genet., 22, 3931-3946.
41. Wang, X., Yan, M.H., Fujioka, H., Liu, J., Wilson-Delfosse, A., Chen, S.G., Perry, G., Casadesus, G. and Zhu, X. (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet., 21, 1931-1944.
42. Mao, P., Manczak, M., Shirendeb, U.P. and Reddy, P.H. (2013) MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim. Biophys. Acta, 1832, 2322-2331.
43. Magrané, J., Cortez, C., Gan, W.B. and Manfredi, G. (2014) Abnormal mitochondrial transport and morphology are common pathological denominators in SOD1 and TDP43 ALS mouse models. Hum. Mol. Genet., 23, 1413-1424.
44. Trushina, E., Dyer, R.B., Badger, J.D. II, Ure, D., Eide, L., Tran, D. D., Vrieze, B.T., Legendre Guillemin, V., McPherson, P.S., Mandavilli, B.S. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell Biol., 24, 8195-8209.
45. Guo, X., Disatnik, M.H., Monbureau, M., Shamloo, M., Mochly-Rosen, D. and Qi, X. (2013) Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J. Clin. Invest., 123, 5371-5388.
46. Borrell-Pagès, M., Zala, D., Hmbert, S. and Saudou, F. (2006) Huntington's disease: fromhuntingtin function and dysfunction to therapeutic strategies. Cell Mol. Life Sci., 63, 2642-2660.
47. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
48. Tabrizin, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M. and Schapira, A.H. (1999) Biochemical abnormalities and excitotoxicity in Huntington'sdiseasebrain. Ann. Neurol., 45, 25-32.
49. Pandey, M., Varghese, M., Sindhu, K.M., Sreetama, S., Navneet, A.K., Mohanakmar, K.P. and Usha, R. (2008) MitochondrialNAD +-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J. Neurochem., 104, 420-434.
50. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and MacDonald, M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
51. Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M., Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet., 9, 503-513.
52. Reddy, T.P., Manczak, M., Calkins, M.J., Mao, P., Reddy, A.P., Shirendeb, U., Park, B. and Reddy, P.H. (2011) Toxicity of neurons treated with herbicides and neuroprotection by mitochondria targeted antioxidant SS31. Int. J. Environ. Res. Public Health, 8, 203-221.
53. Hall, E.D. and Bosken, J.M. (2009) Measurement of oxygen radicals and lipid peroxidation in neural tissues. Curr. Protoc. Neurosci., 7, 1-51.